JMP Securities Cuts BioAtla (NASDAQ:BCAB) Price Target to $5.00

BioAtla (NASDAQ:BCAB) had its target price cut by JMP Securities from $12.00 to $5.00 in a research report sent to investors on Thursday morning, Benzinga reports. They currently have a market outperform rating on the stock.

Separately, HC Wainwright restated a buy rating and issued a $7.00 target price on shares of BioAtla in a report on Wednesday, May 15th.

BioAtla Stock Down 18.6 %

Shares of BioAtla stock opened at $1.71 on Thursday. The stock has a market cap of $82.29 million, a price-to-earnings ratio of -0.69 and a beta of 1.23. BioAtla has a twelve month low of $1.24 and a twelve month high of $4.02. The company’s fifty day moving average is $2.84 and its 200 day moving average is $2.42.

BioAtla (NASDAQ:BCAB) last issued its quarterly earnings results on Tuesday, March 26th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.12. As a group, equities analysts anticipate that BioAtla will post -1.72 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioAtla

A number of hedge funds have recently added to or reduced their stakes in BCAB. Price T Rowe Associates Inc. MD acquired a new position in BioAtla during the first quarter worth $45,000. Virtu Financial LLC acquired a new stake in shares of BioAtla in the 1st quarter worth about $103,000. Pale Fire Capital SE lifted its position in BioAtla by 204.6% in the 4th quarter. Pale Fire Capital SE now owns 48,383 shares of the company’s stock valued at $119,000 after acquiring an additional 32,500 shares in the last quarter. Panagora Asset Management Inc. bought a new position in BioAtla in the 3rd quarter valued at about $90,000. Finally, PVG Asset Management Corp acquired a new position in BioAtla during the 4th quarter valued at about $161,000. Institutional investors and hedge funds own 77.23% of the company’s stock.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.